Gale Scott

The use of interferon to treat hepatitis C infections has fallen out of favor with the advent of new antivirals and drug combinations that have fewer side effects. But in a study presented at the 2015 International Liver Congress in Vienna, Austria, researchers from the UK said that physicians should put interferon back on the treatment menu.

The assumption used to be that after a liver transplant patients would need to take immunosuppressive drugs for years, even for life. A team of German researchers say that for about half of adult patients, that is no longer true.

As good news about new treatments for hepatitis C infections continues to dominate the 2015 International Liver Congress, Texas researchers today reported more success with sofosbuvir and daclatasvir.

One cure for polycystic liver disease is a liver transplant-but since the disease is not fatal (the liver continues to do its job despite the problems the condition causes for patients), physicians face a treatment dilemma. A Belgian team offers an objective way to make the decision.

A new antiviral combination is showing promise in treating patients with both chronic kidney disease and chronic hepatitis C, Texas researchers reported at the International Liver Congress in Vienna, Austria.

When it comes to developing heart disease, patients who have non-alcoholic steatohepatitis (NASH) liver disease are at greater risk of both cardiovascular illness and death than patients with non-alcoholic fatty liver disease a UK team reported today at the International Liver Congress in Vienna, Austria.

Researchers in India have found a reliable and sensitive marker to predict how close to organ failure seriously ill patients with liver disease may be.

Active immunization for hepatitis B can be a cheaper, safe way to prevent infections that occur when liver transplant recipients are infected by donors' organs.

After partial hepatectomy, the liver does not need an environment rich in microbes and microbial products to regenerate, a Swiss team reports. The finding contradicts earlier studies.

French researchers found that patients with hepatitis C infections due to genotypes 4 and 5 did well on a combination of ledipasvir and sofosbuvir (Harvoni/Gilead.) The drug got FDA approval last year but since then there have been few reports on how well it is doing in the real world.

A new antiviral combination that shows dramatic results in getting a response from patients with both chronic kidney failure and hepatitis C is proving versatile.

Translational medicine should work for many patients with liver cancer, a French research team reported this morning at the 2015 International Liver Congress.

So far there are no approved pharmaceuticals for treating a common liver disease, non-alcoholic steatohepatitis (NASH). But in a second encouraging drug development reported at the International Liver Congress in Vienna, Austria this morning, Austria, researchers said they like what they see in a trial of Liraglutide (Saxenda/ NovoNordisk).

An investigational diabetes drug called remogliflozin etabonate appears to also show promise for treating a common liver disease, non-alcoholic steatohepatitis (NASH) and its precursor non-alcoholic fatty liver disease (NAFLD).

High levels of vitamin D3 appear to induce weight gain in mice that were fed a high-fat diet, a research team found.

Many studies have looked at the link between vitamin D deficiency and liver disease. A Korean team recently examined whether vitamin D deficiency played a pivotal role in abnormal liver enzymes.

The intracellar lipid deposition, mitrochondrial dysfunction, and insulin resistance associated with non-alcoholic fatty liver disease is likely regulated by microRNAs, particularly in obese patients.

Patients with severe cirrhosis, those who are waiting for a liver transplant, or have recurrent hepatitis C infection following treatment are desperately ill. Researchers at the 2015 International Liver Congress reported that a fixed dose combination of ledipasvir/sofosbuvir given in combination with ribavirin helped many of these patients, according to the results from the SOLAR 2 trial.

To the legal and criminal justice system, people with behavioral-variant frontotemporal dementia (bvFTD) are responsible for any moral or legal transgressions questions that assumption.

Stroke episodes are ideally suited for assessing the concept of value-based care, a Kentucky team argues.

With all the focus on the hazards of concussion brain injury in professional US football, Australian researchers decided it was time to take a look at the risks in rugby.

A diet rich in fish, green leafy vegetables, nuts and whole grains appears to lead to an increase in brain volume.

Stroke creates language deficits related to brain tissue damaged directly by lesions in cortical and subcortical regions. Disruptions of white matter connectivity also affect multiple domains of behavior and cognition.

Huntington's Disease (HD) is an autosomal dominant progressive neurodegenerative disorder. In addition to the central nervous system disturbance the ailment causes, there is increasing evidence the genetic abnormality also affects peripheral organs and tissues.

Patients with multiple sclerosis (MS) often have sensitivity to heat that worsens their symptoms. In earlier studies with MS patients, a device system that cools body temperature by chilling one palm proved useful in helping them walk faster and longer. But patients need to be motivated to use it successfully.

Results from one module of the CaMEO (Chronic Migraine Epidemiology and Outcomes) study show that patients with chronic migraine are not the only ones who suffer.

An estimated 11,000 attendees from 105 countries are converging in Vienna, Austria for the 50th International Liver Congress, hosted by the European Association for the Study of the Liver (ILC/EASL). Some 200 journalists -- including a team from MD Magazine--are on hand to report the news. Eagerly awaited trials include those of two drugs that show promise for treating a common liver disease associated with obesity, known medically as non-alcoholic steatohepatitis (NASH) and its precursor non-alcoholic fatty liver disease (NAFLD).

Patients with Parkinson's disease frequently look for treatments that physicians consider alternative or complementary therapies.

Patients at high risk of carotid stenosis are candidates for carotid artery stenting. Researchers looked at results when patients had the procedure when they were 80 years old.

In a case reported in a poster session, a team describes a patient whose infection with E. cloacae caused a stroke.